Claris Bio
Latest round
- Series B
Last raised
- Jul 2026
Total raised
- $128M
Investors
- 10
About Claris Bio
Based in the US, Claris Biotherapeutics, Inc. operates as a provider of topical formulation to deal with corneal issues. Founded in 2018 and based in New Jersey, US, Claris Biotherapeutics, Inc. operates as a biotechnology company that is focused on corneal disease therapies. Stephen Brady appointed President and Chief Executive Officer, Brian Baum named Chief Commercial Officer, and Marc de Garidel appointed Chairman of the Board. In July 2026, Claris Biotherapeutics, Inc. The company offers a wide range of treatment solutions to treat corneal ulcers, dry eye disease, corneal edema, microbial keratitis, thermal burn, neurotrophic keratitis, and many others.1% ophthalmic solution.
Who invested in Claris Bio
10 investors across 2 rounds
See all investors in Claris Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Claris Bio
Who invested in Claris Bio?
Claris Bio has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Claris Bio raised?
Claris Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Claris Bio last raise money?
Claris Bio's most recent round on record is a Series B, in Jul 2026.
What does Claris Bio do?
Based in the US, Claris Biotherapeutics, Inc.
Where is Claris Bio headquartered?
Claris Bio is headquartered in Jersey City, US.
Which VCs invest in companies like Claris Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Claris Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Claris Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.